利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.027 秒)

    Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
    3.
    发明授权
    Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM 有权

    公开(公告)号：US09744177B2

    公开(公告)日：2017-08-29

    申请号：US14638763

    申请日：2015-03-04

    申请人： Fernand Labrie ,  Sylvain Gauthier

    发明人： Fernand Labrie ,  Sylvain Gauthier

    IPC分类号： A61K31/5685 ,  A61K38/24 ,  A61K31/453 ,  A61K45/06

    CPC分类号： A61K31/5685 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0053 ,  A61K31/453 ,  A61K38/24 ,  A61K45/06 ,  A61K2300/00

    摘要： Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low DHEA or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and a selective estrogen receptor modulator (SERM) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, Alzheimer's disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

    Helix 12 directed pharmaceutical products
    4.
    发明申请
    Helix 12 directed pharmaceutical products 有权
    Helix 12定向药品

    公开(公告)号：US20050250749A1

    公开(公告)日：2005-11-10

    申请号：US11030850

    申请日：2005-01-07

    申请人： Fernand Labrie ,  Shankar Singh ,  Sylvain Gauthier ,  Yvon Frechette ,  Sylvain Chenard ,  Rock Breton

    发明人： Fernand Labrie ,  Shankar Singh ,  Sylvain Gauthier ,  Yvon Frechette ,  Sylvain Chenard ,  Rock Breton

    IPC分类号： A61K31/56 ,  A61K31/565 ,  A61K31/58 ,  A61P35/00 ,  C07J1/00

    CPC分类号： C07J1/00

    摘要： Compounds having the structure or their salts: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Some of these compounds having tissue-specific antiandrogenic activity and tissue-specific androgenic activity can be used to treat or reduce the risk of developing diseases related to loss of androgenic stimulation. Combinations with other active pharmaceutical agents are also disclosed.

    摘要翻译： 具有结构或其盐的化合物用于治疗或减少获得雄激素依赖性疾病如前列腺癌，良性前列腺增生症，多囊卵巢综合征，痤疮，多毛症，皮脂溢，雄激素性脱发和男性秃发的可能性。 它们可以与药学上可接受的稀释剂或载体一起配制或以其它方式制成任何药物剂型。 具有组织特异性抗雄激素活性和组织特异性雄激素活性的这些化合物中的一些可用于治疗或降低与丧失雄激素刺激相关的疾病的风险。 还公开了与其它活性药剂的组合。

    TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM
    6.
    发明申请
    TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM 有权
    治疗与雄性不孕症状或疾病与SEM STEROID前列腺素联合SERM

    公开(公告)号：US20150250802A1

    公开(公告)日：2015-09-10

    申请号：US14638763

    申请日：2015-03-04

    申请人： Fernand Labrie ,  Sylvain Gauthier

    发明人： Fernand Labrie ,  Sylvain Gauthier

    IPC分类号： A61K31/5685 ,  A61K38/24 ,  A61K31/453

    CPC分类号： A61K31/5685 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0053 ,  A61K31/453 ,  A61K38/24 ,  A61K45/06 ,  A61K2300/00

    摘要： Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low DHEA or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and a selective estrogen receptor modulator (SERM) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, Alzheimer's disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

    摘要翻译： 用于预防，减少或消除男性雄激素缺乏症状或疾病的发生率的方法，包括男性性腺机能减退相关症状和与低血清睾酮和/或低DHEA或低总雄激素相关的疾病，包括涉及给药的易感温血动物 一类量的类固醇前体，特别是脱氢表雄酮（DHEA）和选择性雌激素受体调节剂（SERM）（尤其是阿曲比芬），二者的抗雌激素或前药。 症状或疾病是性欲丧失，勃起功能障碍，疲劳，能量损失，抑郁，骨丢失，肌肉损失，肌肉无力，脂肪堆积，记忆丧失，认知丧失，阿尔茨海默氏病，痴呆，身体毛发丧失，生育问题 ，失眠，男子女性发育不良，贫血，潮热，汗水，健康感，肥胖症，骨质疏松症，高胆固醇血症，高脂血症，动脉粥样硬化，高血压，胰岛素抵抗，心血管疾病和2型糖尿病。 还公开了用于递送本发明有用的活性成分和试剂盒的药物组合物。

    Helix 12 directed pharmaceutical products
    7.
    发明授权
    Helix 12 directed pharmaceutical products 有权
    Helix 12定向药品

    公开(公告)号：US09090651B2

    公开(公告)日：2015-07-28

    申请号：US11030850

    申请日：2005-01-07

    申请人： Fernand Labrie ,  Shankar Singh ,  Sylvain Gauthier ,  Yvon Frechette ,  Sylvain Chenard ,  Rock Breton

    发明人： Fernand Labrie ,  Shankar Singh ,  Sylvain Gauthier ,  Yvon Frechette ,  Sylvain Chenard ,  Rock Breton

    IPC分类号： A61K31/565 ,  C07J41/00 ,  C07J1/00

    CPC分类号： C07J1/00

    摘要： Compounds having the structure or their salts: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Some of these compounds having tissue-specific antiandrogenic activity and tissue-specific androgenic activity can be used to treat or reduce the risk of developing diseases related to loss of androgenic stimulation. Combinations with other active pharmaceutical agents are also disclosed.

    摘要翻译： 具有结构或其盐的化合物用于治疗或减少获得雄激素依赖性疾病如前列腺癌，良性前列腺增生症，多囊卵巢综合征，痤疮，多毛症，皮脂溢，雄激素性脱发和男性秃发的可能性。 它们可以与药学上可接受的稀释剂或载体一起配制或以其它方式制成任何药物剂型。 具有组织特异性抗雄激素活性和组织特异性雄激素活性的这些化合物中的一些可用于治疗或降低与丧失雄激素刺激相关的疾病的风险。 还公开了与其它活性药剂的组合。

    Traffic-signalling system
    9.
    发明申请
    Traffic-signalling system 有权
    交通信号系统

    公开(公告)号：US20050102872A1

    公开(公告)日：2005-05-19

    申请号：US10715490

    申请日：2003-11-19

    申请人： Marc-Andre Seguin ,  Richard Seguin ,  Sylvain Gauthier

    发明人： Marc-Andre Seguin ,  Richard Seguin ,  Sylvain Gauthier

    IPC分类号： E01F9/669 ,  G08G1/09 ,  E01F9/00

    CPC分类号： E01F13/06 ,  E01F9/669

    摘要： The present invention provides a traffic-signalling device suitable for providing information to oncoming traffic. The traffic-signalling device comprises a moveable member suitable for attachment to a support and a solar powered drive system. The moveable member is operative to move between a first position and a second position, wherein in the second position the traffic-signalling device is operative to provide information to oncoming traffic. The solar-powered drive system is suitable for causing the moveable member to move between the first position and the second position.

    摘要翻译： 本发明提供一种适于向迎面而来的业务提供信息的业务信令装置。 交通信号装置包括适于附接到支撑件和太阳能驱动系统的可移动构件。 可移动构件可操作以在第一位置和第二位置之间移动，其中在第二位置，交通信号装置可操作以向迎面而来的交通提供信息。 太阳能驱动系统适于使可移动构件在第一位置和第二位置之间移动。